ITM-52

ITM-52 is an investigational targeted radionuclide therapy being developed by ITM Isotope Technologies Munich for the treatment of folate receptor alpha (FRα)-positive solid tumors, particularly ovarian cancer and non-small cell lung cancer adenocarcinoma.[4][7][14] It consists of two components: actinium-225, a high‑energy alpha‑emitting medical radioisotope, and a proprietary FRα-targeting folate variant (FRαTM) supplied under license from Merck KGaA that binds with high affinity to FRα on tumor cells while sparing most normal tissues.[4][2][12][14] By delivering actinium-225 directly to FRα-overexpressing cancer cells, ITM-52 is designed to induce lethal DNA damage via alpha radiation, and forms part of a radiotheranostic pair with the FRα-targeted PET imaging agent ITM-55D/ITM-55 (18F-AzaFol) to enable patient selection and treatment monitoring.[4][1][7][12][14] ITM-52 remains in preclinical development, with ITM intending to advance it to phase I clinical testing for hard‑to‑treat FRα-positive solid tumors, including ovarian and lung cancers.[2][7][12][15]